I realize that every company but Precigen blows your socks off but this is clearly not a leap frog.
Precigen 2009 had a 30% response rate when combined with the inferior MerckAG checkpoint on patients who had already failed Keytruda. Even if you only add 18% to 30% you get a better OR for 2009 if given first line with Keytruda.
Interesting how they had little info on the 15 patients treated that had failed Keytruda initially. They must have started the trial with this cohort.
More than likely Precigen will be allowed to shift their new 2009 trial to first line after treating a number of patients second line and then including the first line cohort that cohort into a larger pinitol trial.